Litcius/Paper detail

First-line avelumab for patients with PD-L1-positive metastatic or locally advanced urothelial cancer who are unfit for cisplatin

Roberto Iacovelli, Chiara Ciccarese, Matteo Brunelli, Nicola Battelli, Consuelo Buttigliero, Claudia Caserta, Sebastiano Buti, Daniele Santini, Claudia Carella, Luca Galli, Elena Verri, Paola Ermacora, Sara Merler, Cristina Masini, Rocco De Vivo, Laura Milesi, F. Spina, Mimma Rizzo, Isabella Sperduti, Giuseppe Fornarini, Giampaolo Tortora

2022Annals of Oncology24 citationsDOI

Topics & Concepts

MedicineInternal medicineCisplatinDurvalumabOncologyTolerabilityChemotherapyClinical endpointUrothelial cancerCancerMetastatic Urothelial CarcinomaBladder cancerUrologyAdverse effectClinical trialImmunotherapyNivolumabUrothelial carcinomaBladder and Urothelial Cancer TreatmentsCancer Immunotherapy and BiomarkersEsophageal Cancer Research and Treatment
First-line avelumab for patients with PD-L1-positive metastatic or locally advanced urothelial cancer who are unfit for cisplatin | Litcius